CGRP Inhibitors Market Size, Share, and Industry Analysis, By Drug Type (Monoclonal Antibodies and CGRP Antagonists), By Indication (Preventive Migraine and Acute Migraine), By Route of Administration (Oral and Parenteral), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Pharmacies), and Regional Forecast, 2025-2032

The global CGRP inhibitors market is witnessing significant growth due to the increasing adoption of CGRP inhibitors, driven by a combination of several factors such as the increasing prevalence of migraine, proven safety and efficacy, advancements in treatment patterns, enhanced accessibility of these drugs, and supportive regulations in various countries. These factors are also influenced by the rising awareness of migraine treatment, contributing to the market expansion.

• For instance, according to an article published by NCBI in September 2023, CGRP inhibitors have demonstrated high efficacy in clinical trials, showing the ability to reduce migraine frequency by over 50% for many patients. This proven efficacy of CGRP inhibitors in migraine is anticipated to boost its sales, driving market growth over the coming years.

CGRP Inhibitors Market Driver

Rising Prevalence of Migraine to Boost the Market Growth

Over the past few years, there has been a significant rise in cases of migraine, which is creating a significant demand for effective therapeutic options such as CGRP inhibitors globally. CGRP inhibitors offer a targeted approach that has proven effective in reducing the frequency and severity of migraine attacks. Such a scenario is expected to increase its adoption in migraine prevention and treatment, thereby boosting market growth over the coming years.

• For instance, according to Nature Reviews Neurology, in January 2023, the global prevalence of migraines was estimated to be 14.0–15.0%. Such high prevalence is anticipated to boost the demand for treatment options, including CGRP inhibitors, fueling the market growth.

Download Free sample to learn more about this report.

According to data published by The Journal of Headache and Pain, India accounted for the highest number of migraine incidents, with 17.9 million cases in 2019.

CGRP Inhibitors Market Restraint

High Treatment Costs May Hamper the Market Growth

One of the most significant barriers to the adoption of CGRP inhibitors is their high cost. The price of these innovative therapies can be prohibitively expensive, which may limit access for several patients, particularly in regions with constrained healthcare budgets. These affordability concerns often result in patients being unable to secure insurance coverage or reimbursement, further complicating access to these treatments. Such a scenario is anticipated to hinder the market growth.

• For instance, according to an article published by Healthline Media LLC., in May 2024, the annual cost for one type of CGRP migraine treatment is approximately USD 6,900, which breaks down to about USD 575 per month. Such high costs may limit the adoption of CGRP inhibitors for migraine treatment, thereby hindering market growth.

CGRP Inhibitors Market Opportunity

Expanding Use of CGRP-targeted Medication in Chronic Migraine May Spur Market Expansion

In recent years, there has been a growing interest in combining different CGRP-targeted treatments. Several research studies indicate that co-administration of CGRP therapies may enhance therapeutic outcomes for certain patients with chronic migraine. This is anticipated to represent several opportunities for CGRP inhibitors, supporting market expansion in the near future.

• For instance, in April 2024, a study by the Journal of Headache and Pain reported that anti-CGRP medications provide an effective and well-tolerated treatment option for migraines, especially in cases of chronic migraine. Additionally, the research indicated that combining anti-CGRP drugs with onabotulinumtoxinA may be beneficial for patients with resistant chronic migraines, which is anticipated to represent novel opportunities for the use of CGRP inhibitors, contributing to market growth.

Segmentation

Key Insights

The report covers the following key insights:

• Prevalence of Migraine, By Key Countries, 2023
• Key Industry Developments (Mergers, Acquisitions, and Partnerships)
• New Product Launches/Approvals, by Key Players
• Pipeline Analysis, By Key Players
• Impact of COVID-19 on the Market

Analysis by Drug Type

In terms of on drug type, the market is subdivided into monoclonal antibodies and CGRP antagonists.

The CGRP antagonists segment is expected to hold a major share of the global market. The segment growth can be attributed to the increasing product approvals by regulatory authorities, considering the high demand for effective migraine treatments and also the proven efficacy of these drugs.

• For instance, in April 2023, the FDA approved Pfizer Inc.'s Zavzpret (zavegepant) nasal spray for the treatment of acute migraine with or without aura in adults. Such approvals leading to high penetration of CGRP antagonists are projected to propel the segment growth over the forthcoming years.

Analysis by Indication

Based on indication, the market is fragmented into preventive migraine and acute migraine.

The acute migraine segment is expected to hold a major share of the global market. The segment growth can be attributed to the increasing number of clinical studies for CGRP inhibitors in acute migraine treatment. This may lead to their high utilization due to a significant burden worldwide.

• For instance, in August 2024, an article published by NCBI stated that Ubrogepant demonstrated favorable results regarding safety, efficacy, and tolerability in the treatment of acute migraine during phase 3 randomized trials. This is expected to boost its utilization in acute migraine, thereby leading to an increase in product approvals for this condition and boosting the segment growth.

Analysis by Route of Administration

Based on the route of administration, the market is divided into oral and parenteral.

The parenteral segment is expected to hold a substantial share of the global market during the forecast period. The segment growth can be attributed to the high availability of large molecules, such as monoclonal antibodies, in parenteral routes to avoid their degradation by the stomach. The rising demand for this class of drugs in migraine treatment is anticipated to boost the segment growth during the forecast period.

• For instance, according to data published by the Washington State Healthcare Authority in March 2021, erenumab (Aimovig), galcanezumab (Emgality), and fremanuzumab (Ajovy) are some of the subcutaneously administered CGRP antagonists used for the prevention of migraine headache in adults. The rising adoption of these drugs in migraine treatment is projected to boost the segment growth over the forthcoming years.

Analysis by Distribution Channel

Based on distribution channel, the market is divided into hospital pharmacies, drug stores & retail pharmacies, and online pharmacies.

The drug stores & retail pharmacies segment is projected to hold the largest share during the projection period. The growth of the segment is attributed to the increasing number of retail pharmacies along with the increasing tie-ups of these pharmacies with prominent companies to increase the accessibility and affordability of CGRP inhibitors for migraine treatment globally.

• For instance, in January 2023, Reliance Retail shared plans to open over 2,000 standalone pharmacy stores in a year. This significant increase in retail pharmacies, supporting the accessibility and affordability of CGRP inhibitors, is expected to fuel the segment growth over the coming years.

Regional Analysis

To gain extensive insights into the market, Download for Customization

Based on region, the market has been studied across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America accounted for the largest share of the global CGRP inhibitors market in 2023. The region's growth is attributed to the significant burden of migraine across the region's key countries, including the U.S. and Canada, which is projected to surge the usage of effective drugs, including CGRP inhibitors.

• For instance, according to data published by the Journal of Head and Face Pain in May 2024, a study demonstrated that the prevalence of migraine in the U.S. was around 11.7% to 14.7%. The proportion of people with migraine and moderate-to-severe disability has been increasing, leading to high adoption of CGRP inhibitors supporting the regional market growth.

Europe is the second-largest market based on the demand for CGRP inhibitors. The growth is attributed to the increasing penetration of prominent players in the region with CGRP inhibitors through direct presence and distribution network, leading to its high usage.

The Asia Pacific is expected to grow at the highest CAGR during the forecast period. The region's growth can be attributed to the rising occurrence of migraines due to a combination of cultural, lifestyle, and environmental factors, including stress, sleep deprivation, and other factors in the region. This may lead to an increase in the demand for CGRP inhibitors, propelling the regional market growth.

• For instance, according to data published by the Journal of Population Therapeutics and Clinical Pharmacology in January 2024, from an Indian perspective, the most common migraine triggers were emotional stress (97.5%), weather change (69%), physical exertion (64.5%), missed meals (63.5%), traveling (55.5%), and sleep deprivation (55%). Such factors are anticipated to boost the demand for migraine treatment, contributing to regional market growth.

Key Players Covered

The global CGRP inhibitors market is consolidated, with several companies offering CGRP inhibitor drugs.

The report includes the profiles of the following key players:

• Amgen Inc. (U.S.)
• AbbVie Inc. (U.S.)
• Pfizer Inc. (U.S.)
• Lundbeck A/S (Denmark)
• Eli Lilly and Company (U.S.)
• Teva Pharmaceutical Industries Ltd. (Israel)

Key Industry Developments

• In April 2023, AbbVie Inc., received FDA approval for an expanded indication of QULIPTA (atogepant) for the preventive treatment of chronic migraine in adults.
• In September 2021, AbbVie Inc., received FDA approval for QULIPTA (atogepant) for the preventive treatment of episodic migraine in adults.